Drug profile · INN
levobetaxolol hydrochloride
BETAXON
levobetaxolol hydrochloride (BETAXON) is a beta-1 adrenergic receptor antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — levobetaxolol hydrochloride
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
levobetaxolol hydrochloride (BETAXON) is a beta-1 adrenergic receptor antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Beta-1 adrenergic receptor antagonist
Primary target: Beta-1 adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is levobetaxolol hydrochloride?
levobetaxolol hydrochloride (BETAXON) is a beta-1 adrenergic receptor antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for levobetaxolol hydrochloride?
BETAXON is a marketed brand name for levobetaxolol hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of levobetaxolol hydrochloride?
levobetaxolol hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.